

## Press Release August 2012

### **Secretary of State for Health announces investment plan in Bio Products Laboratory (BPL)**

On Friday, 13 July, the Secretary of State for Health announced that the UK Department of Health is looking at strategic options to secure private investment in Plasma Resources UK, which is the holding company for BPL and DCI Biologicals.

Increased investment will enable BPL to drive development of its product range, invest in the capital infrastructure, and extend its business opportunities around the globe. BPL is an excellent proposition for any investor, as it is currently selling a strong portfolio of products in 45 countries worldwide. If private investment is obtained, this will accelerate the timescales in which BPL can achieve our business objectives.

Mark Webster, Chief Executive Officer, BPL commented "This is an exciting development for BPL. The objective of this programme is to attract the level of investment in our plant and our workforce needed to fulfil the requirements of our long-term business plan."

In carrying out the strategic programme, the Department of Health has put safeguards in place to ensure continuity of supply and the retention of jobs within the bioscience sector. In practical terms this means that you can rest assured that your day-to-day interactions with BPL will continue uninterrupted, and that BPL will remain focused on delivering high quality products to patients and customers.

#### Note to Editors

1. Bio Products Laboratory Limited (BPL) is committed to provide a continuous supply of safe, reliable, high quality plasma-derived products and forging commercial alliances worldwide

For more information contact:

Jackie Lawton

Bio Products Laboratory Limited

Contact number: 07881 920408

CO/IG/0712/0005.